We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$169B
Turnover
4.85%
1-Year Est. Return
114.72%
This Fund
S&P 500
This Quarter
Est. Return
+11.96%
1 Year Est. Return
+114.72%
3 Year Est. Return
+234.44%
5 Year Est. Return
+291.25%
10 Year Est. Return
+1,263.36%
AUM
$109B
AUM Growth
+$5.89B
(+5.7%)
Cap. Flow
-$3.72B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
32.97%
Holding
343
New
8
Increased
53
Reduced
229
Closed
9
Avg Time Held
5.7
years
Top 10 Avg Time Held
5
years
Top 20 Avg Time Held
5.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Splunk Inc
SPLK
|
+$164M |
| 2 |
Fidelity National Information Services
FIS
|
+$140M |
| 3 |
Intel
INTC
|
+$124M |
| 4 |
GSK
GSK
|
+$111M |
| 5 |
Mobileye
MBLY
|
+$62.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$753M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
+$370M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Charles Schwab
SCHW
|
+$197M |
| 5 |
Morgan Stanley
MS
|
+$145M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.81% |
| 2 | Technology | 27.17% |
| 3 | Industrials | 11.89% |
| 4 | Financials | 8.82% |
| 5 | Consumer Discretionary | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Curtiss-Wright
CW
$18.5B
| $190M | 0.17% |
1,140,635
-170,880
| -13% | -$28.5M |
2013 Q3
37 quarters
|
|
102
Citigroup
C
$207B
| $188M | 0.17% |
4,167,046
-146,800
| -3% | -$6.67M |
2017 Q1
23 quarters
|
|
103
Alaska Air
ALK
$4.07B
| $184M | 0.17% |
4,290,237
-169,200
| -4% | -$7.46M |
2013 Q2
38 quarters
|
|
104
DuPont de Nemours
DD
$17.8B
| $175M | 0.16% |
2,026,868
+340,857
| +20% | +$27.2M |
2013 Q2
38 quarters
|
|
105
Revvity
RVTY
$17.3B
| $170M | 0.16% |
1,215,565
-75,305
| -6% | -$10.1M |
2013 Q2
38 quarters
|
|
106
Keysight
KEYS
$58.2B
| $163M | 0.15% |
955,285
-103,580
| -10% | -$17.7M |
2014 Q4
32 quarters
|
|
107
Xencor
XNCR
$1.78B
| $162M | 0.15% |
6,216,903
+526,672
| +9% | +$14.7M |
2013 Q4
36 quarters
|
|
108
Freeport-McMoran
FCX
$101B
| $160M | 0.15% |
4,200,500
+1,225
| +0% | +$42.8K |
2020 Q4
8 quarters
|
|
109
Sysco
SYY
$40.4B
| $152M | 0.14% |
1,982,650
-51,475
| -3% | -$4.16M |
2021 Q1
7 quarters
|
|
110
Nutanix
NTNX
$18.9B
| $149M | 0.14% |
5,706,333
-535,452
| -9% | -$14.6M |
2017 Q2
22 quarters
|
|
111
Meta Platforms (Facebook)
META
$1.88T
| $148M | 0.14% |
1,228,575
-5,700
| -0.5% | -$669K |
2018 Q1
19 quarters
|
|
112
Edwards Lifesciences
EW
$50.8B
| $147M | 0.13% |
1,966,000
-90,300
| -4% | -$6.96M |
2013 Q2
38 quarters
|
|
113
T-Mobile US
TMUS
$168B
| $145M | 0.13% |
1,037,459
-37,847
| -4% | -$5.44M |
2017 Q1
23 quarters
|
|
114
Mastercard
MA
$540B
| $143M | 0.13% |
412,200
| – | – |
2013 Q2
38 quarters
|
|
115
PayPal
PYPL
$48.9B
| $140M | 0.13% |
1,963,310
-283,650
| -13% | -$22.7M |
2015 Q3
29 quarters
|
|
116
WEX
WEX
$6.17B
| $139M | 0.13% |
848,030
-245,370
| -22% | -$38.2M |
2021 Q1
7 quarters
|
|
117
Burlington
BURL
$16.8B
| $135M | 0.12% |
666,080
-5,470
| -0.8% | -$873K |
2018 Q1
19 quarters
|
|
118
Teradyne
TER
$53.7B
| $134M | 0.12% |
1,536,650
-1,705
| -0.1% | -$146K |
2015 Q3
29 quarters
|
|
|
119
GSK
GSK
$98.2B
| $132M | 0.12% |
3,765,920
+3,324,800
| +754% | +$111M |
2013 Q2
38 quarters
|
|
120
Marriott International
MAR
$101B
| $129M | 0.12% |
866,446
-400
| -0% | -$61.6K |
2015 Q3
29 quarters
|
|
121
Wolfspeed
WOLF
$1.37B
| $129M | 0.12% |
1,866,094
-246,958
| -12% | -$21.9M |
2013 Q2
38 quarters
|
|
122
Otis Worldwide
OTIS
$26.8B
| $127M | 0.12% |
1,626,841
-19,090
| -1% | -$1.41M |
2020 Q2
10 quarters
|
|
123
Autodesk
ADSK
$51.2B
| $127M | 0.12% |
681,400
-23,000
| -3% | -$4.62M |
2017 Q4
20 quarters
|
|
124
Alkermes
ALKS
$6.73B
| $126M | 0.11% |
4,803,330
-544,420
| -10% | -$13M |
2016 Q2
26 quarters
|
|
125
CSX Corp
CSX
$90.2B
| $125M | 0.11% |
4,029,300
| – | – |
2013 Q2
38 quarters
|
|
Similar funds
Primecap Management's Q4 2022 Portfolio in Review
As of Q4 2022, Primecap Management held 343 positions worth $109B, up 5.7% from $103B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Primecap Management withdrew a net $3.72B in Q4 2022, closing 9 positions and reducing 229 holdings. Its most notable exit was Abiomed Inc, an estimated $370M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 33% a quarter earlier, followed by Technology and Industrials.
Against the trend, Primecap Management opened a new position in Mobileye worth $72.3M.
- Primecap Management's largest Q4 2022 buy was Mobileye: 2,061,470 shares worth $72.3M.
- Primecap Management added most to Splunk Inc in Q4 2022, an estimated $164M increase.
- Primecap Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $753M.
- Primecap Management fully exited Abiomed Inc in Q4 2022, selling an estimated $370M.
- Primecap Management's ten largest holdings make up 33% of its $109B portfolio in Q4 2022.
- Primecap Management opened 8 new positions and closed 9 in Q4 2022.
- Primecap Management's portfolio value rose 5.7% quarter-over-quarter to $109B.
Based on Primecap Management's 13F filing for Q4 2022, filed 13 Feb 2023.